Pharmacovigilance study : exploring the role of community pharmacists in adverse drug reactions reporting in Alkharj city, Saudi Arabia by Rabba, Abdullah K. & Ain, Mohammad R.
901
KEY WORDS: ADRs reporting, Alkharj city, community pharmacists, pharmacovigilance.
* Author to whom correspondence should be addressed. E-mail: a.rabba@sau.edu.sa 
Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 34 (5): 901-6 (2015)
Regular article
Received: November 1, 2014
Revised version: March 15, 2015 
Accepted: March 17, 2015
Pharmacovigilance Study: Exploring the Role
of Community Pharmacists in Adverse Drug Reactions
Reporting in Alkharj City, Saudi Arabia
Abdullah K. RABBA* & Mohammad R. AIN
Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University,
Alkharj, Kingdom of Saudi Arabia
SUMMARY. Pharmacovigilance is the science and activities relating to the detection, assessment, under-
standing and prevention of adverse effects or any other drug related problems. Spontaneous adverse drug
reaction (ADR) reporting is the foundation stone of pharmacovigilance activity. A cross sectional survey
was carried out from September 2013 to January 2014 to evaluate the role of community pharmacists in
ADRs reporting, by using a pre-assessed questionnaire with structured face-to-face interviews with com-
munity pharmacists from randomly selected private community pharmacies in Alkharj, Kingdom of Sau-
di Arabia. A total of 53 community pharmacists participated in the study, Results of this study reflected
lack of adequate knowledge regarding ADRs reporting among community pharmacists. Regulatory au-
thorities and professional pharmaceutical organizations in Saudi Arabia need to raise concern and edu-
cate pharmacists on the system of pharmacovigilance.
RESUMEN. La farmacovigilancia es la ciencia y las actividades relacionadas con la detección, evaluación, com-
prensión y prevención de los efectos adversos o cualquier otro problema de la droga. La notificación espontánea
de reacciones adversas a medicamentos (RAM) es la piedra fundamental de la actividad de farmacovigilancia.
Un estudio transversal se llevó a cabo de septiembre de 2013 a enero de 2014 para evaluar el papel de los farma-
céuticos comunitarios en RAMs de informes, mediante un cuestionario pre-evaluados con entrevistas estructura-
das cara a cara con los farmacéuticos de las farmacias privadas seleccionados al azar en Alkharj, Reino de Arabia
Saudita. Un total de 53 farmacéuticos comunitarios participaron en el studio; los resultados reflejan falta de co-
nocimientos adecuados en relación con información sobre ADRs entre los farmacéuticos comunitarios. Las auto-
ridades regulatorias y las organizaciones profesionales de farmacéuticos en Arabia Saudita deben preocuparse
por educar a los farmacéuticos en el sistema de farmacovigilancia.
INTRODUCTION
According to World Health Organization
(WHO), Pharmacovigilance is defined as “the
science and activities relating to the detection,
assessment, understanding and prevention of
adverse effects or any other drug related prob-
lems 1,2. The main scope of pharmacovigilance
is to improve the safe and rational use of
medicines, thereby improving patient care and
public health.
In 1961, thalidomide disaster occurred and in
response to this WHO established its Program
for International Drug Monitoring. Most coun-
tries in the world have their own established ad-
verse drug reactions (ADRs) reporting systems 3.
However, ADRs remain a major cause of both
morbidity and mortality 4–7. Moreover, ADRs are
one of the major factors for hospital admissions
and it varies worldwide 8. In developed coun-
tries such as United States of America (USA),
ADRs ranked as the six leading cause of mortali-
ty 2, and shown to be responsible for 3%-6%
hospital admission of patients of all ages 9. It
has been reported that ADRs cause 7% of all
hospital admissions in the United Kingdom (UK)
10, while in Sweden 13% of patients admission
to the internal wards were result of ADRs 11.
The scope of pharmacovigilance is to promote
patient safety in relation to the use of drugs;
and to support public health programs by pro-
viding reliable, balanced information for the ef-
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fective assessment of the risk-benefit profile of
medications. 
Community pharmacists play an important
role in post marketing surveillance activities,
which are vital in providing important safety in-
formation that cannot realistically be collected
before approval of a drug 12. To prevent or re-
duce harm to patients, procedures to evaluate
and monitor the safety of drugs are extremely
important. Such procedures form the core of
pharmacovigilance programs, however, many
challenges face health care providers in achiev-
ing success following these procedures, espe-
cially, reporting systems.
Pharmacists play a vital role in enhancing in-
dividual’s health care, advancing the body of
knowledge about medications and ensuring safe
and effective use of drugs 13. As part of this re-
sponsibility, pharmacists should proactively
communicate feedback information regarding
safety of medications with regulatory authorities.
As front-line easily accessible health care
providers, pharmacists are most likely to receive
ADRs reports from consumers. In Saudi Arabia
the National Pharmacovigilance Center of the
Saudi Food and Drug Authority (SFDA) is ac-
tively involved in receiving ADRs reports from
pharmacists and other health care professionals
in Saudi Arabia. ADRs reporting forms are avail-
able (http://www.sfda.gov.sa/en/drug/about/
sector_departments/national_pharmacovigi-
lance_center/Pages/reporting_forms.aspx).
Community pharmacists can play an impor-
tant role in patient counseling and should be
able to give basic drug information in terms of
appropriate drug use, administration, dosage,
side effects, storage and drug-drug and drug-
food interactions 14. A number of studies have
been conducted in the Kingdom of Saudi Arabia
on various aspects of pharmacy practice in both
hospital and community pharmacy settings 15–20.
Among these studies, three addressed in detail
the issue of ADRs reporting in Saudi Arabia
15,19,20. However, to our knowledge, none of pre-
viously published reports found to address any
aspect of pharmacy practice or pharmacovigi-
lance in Alkharj city. Alkharj city is located in the
central region of Kingdom of Saudi Arabia with
a population of around 235000 according to the
Central Department of Statistics and Information
of Kingdom of Saudi Arabia in 2010 21.
The main aim of this study was to evaluate
knowledge, attitude, behavior and perception of
ADRs reporting among community pharmacists
in Alkharj city in Saudi Arabia.
MATERIAL AND METHODS
A cross sectional study was carried out from
September 2013 to January 2014, involving ran-
domly selected 65 community pharmacists in
Alkharj city in Kingdom of Saudi Arabia. A self
administered, validated, 37-item questionnaire
was used to assess community pharmacists
knowledge and attitude towards adverse drug
reactions and barriers to their reporting. The
questionnaire was primarily adapted from previ-
ously published literature 15, with some modifi-
cation. In brief, the questionnaire was com-
prised of five sections.
First section consisted of questions regarding
the demographics and pharmacy related infor-
mation. Second section, was used to assess gen-
eral knowledge of ADR reporting and monitor-
ing. Nine questions were listed in this section
using a nominal scale (yes/no), i.e., Do you
know pharmacovigilance system?, Do you know
the common terms used in the ADR reporting
system?, Do you know where to report the
ADR?, Have ever come across the ADR reporting
form?, if you want to report, where to find the
ADR reporting form?, Awareness of laws guiding
ADRs reporting?, Have you ever observed a sus-
pected ADRs?, Have you ever reported a sus-
pected ADRs?, and Do you obtain regular infor-
mation on ADRs?.
Third Section, was used to assess the atti-
tudes and behaviors of pharmacists towards
ADRs reporting and comprised of twelve items,
i.e. Reporting ADRs is part of the professional
role of a pharmacist, Need to discuss the sus-
pected ADR with the prescriber before report-
ing, I had reported an ADR to either the drug
control authorities or SFDA?, I had come across
any ADRs in daily practice within the previous
year, I believe that the science of monitoring
drug safety (pharmacovigilance) is important, I
want to be sure the ADR is related to the drug
before reporting, I do not report ADRs of Over
The Counter (OTC) products supplied by my
pharmacy, I report to get more insight into ADR
questions that I come across in my practice, I
report to show the patient that their concern is
being taken seriously, I always report ADRs be-
cause it is part of pharmaceutical care, ADRs re-
porting should be compulsory, ADRs reporting
should be voluntary.
Fourth section was used to discover barriers
to ADRs reporting. Fourteen items listed in this
section, i.e. No reporting forms available, Re-
porting address unknown, Reporting form too
complicated, Reporting ADRs is time consum-
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ing, All ADRs are known, Want to publish my-
self, Confidentiality, Patient confidence, Fear of
liability, No motivation, Insufficient clinical,
knowledge, Do not know how to report,
Causality uncertain, One report makes no differ-
ence.
This study was approved by the ethical com-
mittee of college of pharmacy of Prince Sattam
Bin Abdulaziz University and fund was granted
by the deanship of scientific research. Verbal
consent was obtained from all study participants
before their participation in this study. Any in-
formation that discloses the responder’s identity
was excluded from the data collected. Only, the
name of community pharmacies were written in
coded form to differentiate the pharmacies such
as chain and independent pharmacies. 
Statistical analysis
Data from questionnaires were analyzed us-
ing Statistical Package for the Social Sciences
(SPSS) version 20.0.
RESULTS
The sample under investigation consisted of
65 community pharmacists who were invited to
participate in this study by filling the question-
naires, and answering oral questions. 53 filled
questionnaires were obtained giving a response
rate of 81%, one pharmacist refused to fill the
questionnaire (1.5%) and 11 (17%) pharmacists
were not able to fill the questionnaires due to
lack of time.
Community pharmacist demographic
characteristics
Vast majority of responders were of young
age with 98% younger than 40 years of age. Fur-
Demographics Frequency (%)
Age group
24-30 39 73.6
(in years)
31-40 13 24.5
41-50 1 1.9
Country of Egypt 51 96
graduation Sudan 2 4
Duration of 1-5 20 37.7
practice experience 6-10 18 34
(in years) >10 15 28.3
For how long have 1-5 25 47.2
been a registered 6-10 15 28.3
pharmacist (in years) >10 13 24.5
Table 1. Demographic Characteristics of Community
Pharmacists.
thermore, community pharmacists in our sample
were predominantly graduated from Egypt (n=
51, 96%) and most of them (n = 51, 96%) had
bachelorette degree in pharmacy. Demographic
characteristics of study participants including
those related to professional experience are
shown in Table 1.
Community pharmacists knowledge of ADR
reporting and pharmacovigilance
Only 25% (n = 13) of the respondents knew
pharmacovigilance system. 34% (n = 18) said
that they know the common terms used in the
ADRs reporting system. Among respondents
who were aware of reporting system, when they
were asked where to report the ADRs, 21% (n =
11) knew where to report the ADRs. However,
81% (n=43) never came across ADRs. Questions
regarding the knowledge of community pharma-
cists along with responses are presented in
Table 2. 
NA Yes No
Questions
Count (%) Count (%) Count (%)
Do you know pharmacovigilance system? 3 (6%) 13 (25%) 37 (70%)
Do you know the common terms used in the ADR reporting system? 3 (6%) 18 (34%) 32 (60%)
Do you know where to report the ADR? 3 (6%) 11 (21%) 39 (74%)
Have ever come across the ADR reporting form? 4 (7%) 6 (11%) 43 (81%)
If you want to report, where to find the ADR reporting form? 6 (11%) 10 (19%) 37 (70%)
Awareness of laws guiding ADRs reporting? 2 (4%) 16 (30%) 35 (66%)
Have you ever observed a suspected ADR? 2 (4%) 18 (34%) 33 (62%)
Have you ever reported a suspected ADR? 2 (4%) 9 (17%) 42 (79%)
Do you obtain regular information on ADRs? 2 (4%) 23 (43%) 28 (53%)
Table 2. Community pharmacists knowledge regarding ADR reporting and pharmacovigilance. NA: not an-
swered.
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Community Pharmacists attitudes and
behaviors toward ADRs reporting
85% (n = 45) of the participating pharmacists
agreed that reporting ADRs is part of the profes-
sional role of a pharmacist. However, only 19%
(n = 10) of participants reported that there is no
need to discuss the suspected ADRs with the
prescriber before reporting. 49% (n = 26) of
pharmacists had noticed an ADR in a patient in
daily practice within the previous year, while
83% (n = 44) had ever reported an ADR to ei-
ther the drug control authorities or Saudi Food
and Drug Authority (SFDA), and importantly,
96% (n = 51) believed that the science of moni-
toring drug safety (pharmacovigilance) is impor-
tant. 
Out of 53 respondent’s data, 79% (n = 42)
believed that they always report ADRs because it
NA Agree Disagree
Questions
Count (%) Count (%) Count (%)
Reporting ADRs is part of the professional role of a pharmacist 1 (2%) 45 (85%) 7 (13%)
Need to discuss the suspected ADR with the prescriber before reporting? 1 (2%) 42 (79%) 10 (19%)
I had reported an ADR to either the drug control authorities or SFDA? 3 (6%) 44 (83%) 6 (11%)
I had come across any ADRs in daily practice within the previous year. 1 (2%) 26 (49%) 26 (49%)
I believe that the science of monitoring drug safety (pharmacovigilance) is important 2 (4%) 51 (96%) 0 (0%)
I want to be sure the ADR is related to the drug before reporting 2 (4%) 46 (87%) 5 (9%)
I do not report ADRs of OTC products supplied by my pharmacy 2 (4%) 20 (38%) 31(58%)
I report to get more insight into ADR questions that I come across in my practice 3 (6%) 44 (83%) 6 (11%)
I report to show the patient that their concern is being taken seriously. 3 (6%) 47 (89%) 3 (6%)
I always report ADRs because it is part of pharmaceutical care 3 (6%) 42 (79%) 8 (15%)
ADRs reporting should be compulsory 2 (4%) 38 (72%) 13 (25%)
ADRs reporting should be voluntary 2 (4%) 37 (70%) 14 (26%)
Table 3. Community pharmacists attitudes and behaviors toward ADR reporting. NA: not answered.
NA Agree Disagree
Questions
Count (%) Count (%) Count (%)
No reporting forms available 1 (2%) 48 (91%) 4 (8%)
Reporting address unknown 2 (4%) 37 (70%) 14 (26%)
Reporting form too complicated 2 (4%) 16 (30%) 35 (66%)
Reporting ADRs is time consuming 2 (4%) 22 (42%) 29 (55%)
All ADRs are known 3 (6%) 27 (51%) 23 (43%)
Want to publish myself 3 (6%) 24 (45%) 26 (49%)
Confidentiality 2 (4%) 42 (79%) 9 (17%)
Patient confidence 2 (4%) 37 (70%) 14 (26%)
Fear of liability 4 (8%) 29 (55%) 20 (38%)
No motivation 4 (8%) 32 (60%) 17 (32%)
Insufficient clinical knowledge 3 (6%) 20 (38%) 30 (57%)
Do not know how to report 4 (8%) 29 (55%) 20 (38%)
Causality uncertain 4 (8%) 39 (74%) 10 (19%)
One report makes no difference 4 (8%) 23 (43%) 26 (49%)
Table 4. Community pharmacists’ barriers contributing to non-reporting of ADR. NA: Not answered.
is part of pharmaceutical care, while only 38% (n
= 20) mentioned that they do not report ADRs of
OTC products supplied by their pharmacy.
About 72% of those surveyed thought that ADR
reporting should be compulsory, while 70%
thought that it should be voluntary (Table 3). 
Community pharmacists’ barriers
contributing to non-reporting of ADRs
Among the barriers contributing to non-re-
porting 91% (n = 48) of responders agreed that
reporting forms are not available, 70% (n = 37)
reporting address unknown, and 79% (n = 42)
agreed that non-reporting is due to confidential-
ity. Interestingly, 51% (n = 27) agreed that all
ADRs are known. Table 4 represents pharma-
cists’ answers regarding barriers to ADR report-
ing.
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DISCUSSION
The present study is the first study of this
type of issue in Alkharj city which tried to assess
the knowledge, attitudes and behavior of com-
munity pharmacists toward spontaneous ADRs
reporting and pharmacovigilance. According to
our findings, response rate was good (81%) and
improved as compared to the report obtained
by Bawazir (71.7%) 15. All the community Phar-
macists were Arabic speakers (From Egypt and
Sudan) and almost similar findings were estab-
lished in previous study 15. This is due to lack of
Saudi pharmacists and also most of the qualified
pharmacy graduates like to join the government
sector because of better salary and other adorn-
ment benefits. However, our findings, regarding
Saudi pharmacists appointments in community
setting found to be contrasting to the expecta-
tion given by Bawazir, 2006 15. There are several
reports from different countries which empha-
sized the problem of the ADRs under-reporting
among pharmacists 22–26. 
Various studies previously published in Asia,
Europe, America, and Africa have shown scarce
knowledge among healthcare professionals re-
garding pharmacovigilance and ADRs reporting
27–31. In a Malaysian study, it was established that
majority of community pharmacists were found
to be unaware of the existence of the national
reporting system 32. Other studies have also ex-
posed that ADRs under-reporting by health pro-
fessionals is commonly attributed to reasons
such as ADR is not serious, ADR is well known,
uncertainty about causal relationship and lack of
time 33 . In accord with these studies, our study
also established lack of sufficient knowledge
among the community pharmacists with regard
to ADRs reporting system in Saudi Arabia and
where to report the ADRs. Our findings is little
bit lower than the results reported previously in
Saudi Arabia by Bawazir 15 and for Hong Kong
Pharmacists by Lee et al. 34 and higher than facts
reported from Holland (1%) 35 and United
Kingdom (7%) 36 where community pharma-
cists were not aware of the ADRs reporting pro-
gram in their countries. 
In this study, participants claimed good atti-
tudes and behaviors on pharmacovigilance and
related aspects. The majority of community
pharmacists in our study had reported an ADR
(83%) and most of them claimed that they had
submitted ADRs to either the drug control au-
thorities or SFDA. In the previous study by
Bawazir 15, the majority of pharmacists surveyed
claimed that they had submitted ADRs to the
pharmaceutical company as well as the Ministry
of Health 15. The fact that 85% of our study par-
ticipants believed that reporting ADRs is part of
the professional role of a pharmacist indicating
an appropriate education concerning this sub-
ject, comparable findings were listed by Vessel
et al. 37. 
In our study, 79% of participants reported
that ADRs reporting is part of pharmaceutical
care while on an average 71% demonstrated that
ADRs reporting should be compulsory or volun-
tary. However, in a study previously conducted
in Saudi Arabia 97% of pharmacists considered
ADRs reporting to be an integral part of phar-
maceutical care 15. In addition, according to a
Turkish study, 89% of pharmacists believed that
the role of pharmacists in ADR reporting is es-
sential 25. 
In this study, one of the most serious barriers
reported by participants is no reporting forms
available, whereas 42% felt that ADRs reporting
is time consuming and a reason for not report-
ing. Although, there is an ADRs reporting sys-
tem in Saudi Arabia available in paper as well as
electronic format, the majority of community
pharmacists in our study are not aware of where
and how to report ADRs. Several studies em-
phasized that the lack of time was a common
factor in preventing ADRs reporting 23,26,30. In a
study performed in Netherlands over 35% of
medical practitioners recorded that reporting
was time consuming and too bureaucratic 38. In
a study performed in UK, 40% of hospital phar-
macists quoted a lack of time to complete ADRs
reports 22. 
CONCLUSION
Community pharmacists play a major role in
pharmacovigilance and their spontaneous re-
porting of suspected ADRs are of crucial impor-
tance to patient safety. Present study showed
that the knowledge of pharmacists concerning
pharmacovigilance and ADR reporting is poor.
The role of pharmacists in ADR reporting was
not clear to majority of pharmacists under inves-
tigation, and the process of ADR reporting in
terms of “How to report? and Where to report?”
is also unknown. However, positive attitudes
were noticed in vast majority of pharmacists in-
volved in this study towards the importance of
pharmacovigilance. 
The regulatory authorities need to raise con-
cern and educate pharmacists on the system of
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pharmacovigilance. Also, there is a greater need
of awareness to promote the reporting of ADRs
by community pharmacists of the kingdom.
These approaches can greatly influence in
bringing reporting culture in community phar-
macists and may lead to improve reporting rates
of ADRs. The major limitation of our study is
that the findings could not be applied to the
wider community pharmacist’s of the kingdom
as study was restricted to Alkharj city only.
Therefore, our recommendation is that several
studies of similar kind especially in community
pharmacist’s setup throughout the kingdom
need to be conducted to know the knowledge,
attitude and behavior of community pharma-
cistss towards ADRs reporting system in King-
dom of Saudi Arabia.
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